S. Sarkar, Lithium induces autophagy by inhibiting inositol monophosphatase, J. Cell Biol, vol.170, pp.1101-1111, 2005.

C. J. Phiel, C. A. Wilson, V. M. Lee, and P. S. Klein, GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides, Nature, vol.423, pp.435-439, 2003.

J. Carmichael, K. L. Sugars, Y. P. Bao, and D. C. Rubinsztein, Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation, J. Biol. Chem, vol.277, pp.33791-33798, 2002.

C. Voisine, Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans, PLoS ONE, vol.2, p.504, 2007.

S. Sarkar, A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin, Hum. Mol. Genet, vol.17, pp.170-178, 2008.

N. Hong, Y. S. Choi, S. Y. Kim, and H. J. Kim, Neuroprotective effect of lithium after pilocarpine-induced status epilepticus in mice, Korean J. Physiol. Pharmacol, vol.21, pp.125-131, 2017.

O. V. Forlenza, V. J. De-paula, and B. S. Diniz, Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders, ACS Chem. Neurosci, vol.5, pp.443-450, 2014.

L. V. Kessing, Association of lithium in drinking water with the incidence of dementia, JAMA Psychiatry, vol.74, pp.1005-1010, 2017.

H. Wei, Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease, Neuroscience, vol.106, pp.603-612, 2001.

N. I. Wood and A. J. Morton, Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation, Brain Res. Bull, vol.61, pp.375-383, 2003.

M. A. Pouladi, NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease, Neurobiol. Dis, vol.48, pp.282-289, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01545519

S. Sarkar and D. C. Rubinsztein, Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations, Autophagy, vol.2, pp.132-134, 2006.

A. Heiseke, Y. Aguib, C. Riemer, M. Baier, and H. M. Schatzl, Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy, J. Neurochem, vol.109, pp.25-34, 2009.

J. Soriano-barcelo, M. T. Alonso, M. B. Traba, A. A. Vilar, and D. A. Kahn, A case with reversible neurotoxicity after 2 years of dementia secondary to maintenance lithium treatment, J. Psychiatr. Pract, vol.21, pp.154-159, 2015.

V. C. Shah, P. Kayathi, G. Singh, and S. Lippmann, Enhance your understanding of lithium neurotoxicity, Prim. Care Companion CNS Disord, vol.17, 2015.

R. M. Hirschfeld, Partial response and nonresponse to antidepressant therapy: current approaches and treatment options, J. Clin. Psychiatry, vol.63, pp.826-837, 2002.

M. Gitlin, Lithium side effects and toxicity: prevalence and management strategies, Int. J. Bipolar Disord, vol.4, p.27, 2016.

J. P. Grunfeld and B. C. Rossier, Lithium nephrotoxicity revisited, Nat. Rev. Nephrol, vol.5, pp.270-276, 2009.

S. J. Tallaksen-greene and R. L. Albin, Treating mouse models of Huntington disease, Neuropsychopharmacology, vol.36, pp.2373-2374, 2011.

A. Mouri, Phase behavior of reverse microemulsions based on Peceol ®, J. Colloid Interface Sci, vol.416, pp.139-146, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00926026

A. Mouri, Water solubilization capacity of pharmaceutical microemulsions based on Peceol ® , lecithin and ethanol, Int. J. Pharm, vol.475, pp.324-334, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02005304

S. Lehmann, Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder, PLoS ONE, vol.9, p.88797, 2014.

A. Mouri, Formulation, physicochemical characterization and stability study of lithium-loaded microemulsion system, Int. J. Pharm, vol.502, pp.117-124, 2016.

E. N. Wilson, BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology, Transl. Psychiatry, vol.7, p.1190, 2017.

S. Brandner and Z. Jaunmuktane, Prion disease: experimental models and reality, Acta Neuropathol, vol.133, pp.197-222, 2017.

A. Relano-gines, Prion replication occurs in endogenous adult neural stem cells and alters their neuronal fate: involvement of endogenous neural stem cells in prion diseases, PLoS Pathog, vol.9, p.1003485, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00854035

A. B. Diack, Insights into mechanisms of chronic neurodegeneration, Int. J. Mol. Sci, 2016.

K. Jendroska, Proteinase-resistant prion protein accumulation in Syrian hamster brain correlates with regional pathology and scrapie infectivity, Neurology, vol.41, pp.1482-1490, 1991.

Y. Kabeya, LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing, EMBO J, vol.19, pp.5720-5728, 2000.

R. J. Baldessarini, L. Tondo, and A. C. Viguera, Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications, Bipolar Disord, vol.1, pp.17-24, 1999.

R. J. Baldessarini, L. Tondo, and J. Hennen, Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders, J. Clin. Psychiatry, vol.60, pp.77-84, 1999.

A. Cipriani, H. Pretty, K. Hawton, and J. R. Geddes, Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials, Am. J. Psychiatry, vol.162, pp.1805-1819, 2005.

R. J. Baldessarini, M. Pompili, and L. Tondo, Suicide in bipolar disorder: risks and management, CNS Spectr, vol.11, pp.465-471, 2006.

L. Daniels and C. M. , Lithium decreases glial fibrillary acidic protein in a mouse model of alexander disease, PLoS ONE, vol.10, p.138132, 2015.

L. Dell'osso, C. Del-grande, C. Gesi, C. Carmassi, and L. Musetti, A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts, Neuropsychiatr. Dis. Treat, vol.12, pp.1687-1703, 2016.

J. A. Quiroz, R. Machado-vieira, C. A. Zarate, and H. K. Manji, Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects, Neuropsychobiology, vol.62, pp.50-60, 2010.

G. Zanni, Lithium increases proliferation of hippocampal neural stem/ progenitor cells and rescues irradiation-induced cell cycle arrest in vitro, Oncotarget, vol.6, pp.37083-37097, 2015.

Y. Arribat, Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease, Acta Neuropathol. Commun, vol.2, p.86, 2014.

B. H. Jeong, Reduction of prion infectivity and levels of scrapie prion protein by lithium aluminum hydride: implications for RNA in prion diseases, J. Neuropathol. Exp. Neurol, vol.68, pp.870-879, 2009.

X. Zhang, Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model, J. Alzheimers Dis, vol.24, pp.739-749, 2011.

Z. Zhu, Lithium suppresses astrogliogenesis by neural stem and progenitor cells by inhibiting STAT3 pathway independently of glycogen synthase kinase 3 beta, PLoS ONE, vol.6, p.23341, 2011.

E. Beurel and R. S. Jope, Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain, J. Neuroinflamm, vol.6, p.9, 2009.

F. Fornai, Lithium delays progression of amyotrophic lateral sclerosis, Proc. Natl Acad. Sci. USA 105, pp.2052-2057, 2008.

M. Gao, X. Yan, and H. R. Weng, Inhibition of glycogen synthase kinase 3beta activity with lithium prevents and attenuates paclitaxel-induced neuropathic pain, Neuroscience, vol.254, pp.301-311, 2013.

V. V. Senatorov, M. Ren, H. Kanai, H. Wei, and D. M. Chuang, Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease, Mol. Psychiatry, vol.9, pp.371-385, 2004.

V. Stambolic, L. Ruel, and J. R. Woodgett, Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells, Curr. Biol, vol.6, pp.1664-1668, 1996.

G. V. De-ferrari and N. C. Inestrosa, Wnt signaling function in Alzheimer's disease, Brain Res. Brain Res. Rev, vol.33, pp.1-12, 2000.

E. M. Toledo and N. C. Inestrosa, Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease, Mol. Psychiatry, vol.15, pp.272-285, 2010.

H. X. Su, Mutations of C-reactive protein (CRP) -286 SNP, APC and p53 in colorectal cancer: implication for a CRP-Wnt crosstalk, PLoS ONE, vol.9, p.102418, 2014.

J. Sun, Remarkable impairment of Wnt/-catenin signaling in the brains of the mice infected with scrapie agents, J. Neurochem, vol.136, pp.731-740, 2016.

A. Caricasole, Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain, J. Neurosci, vol.24, pp.6021-6027, 2004.

M. H. Magdesian, Amyloid-beta binds to the extracellular cysteine-rich domain of frizzled and inhibits wnt/beta-catenin signaling, J. Biol. Chem, vol.283, pp.9359-9368, 2008.

M. C. Rosi, Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease, J. Neurochem, vol.112, pp.1539-1551, 2010.

S. Bayod, Downregulation of canonical Wnt signaling in hippocampus of SAMP8 mice, Neurobiol. Aging, vol.36, pp.720-729, 2015.

P. Polakis, Wnt signaling in cancer, Cold Spring Harb. Perspect. Biol, 2012.

Y. Motoi, K. Shimada, K. Ishiguro, N. Hattori, and . Lithium, ACS Chem. Neurosci, vol.5, pp.434-442, 2014.

K. Shimada, Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion, Neurobiol. Dis, vol.46, pp.101-108, 2012.

R. Goold, C. Mckinnon, and S. J. Tabrizi, Prion degradation pathways: potential for therapeutic intervention, Mol. Cell. Neurosci, vol.66, pp.12-20, 2015.

B. Jonchere, A. Belanger, C. Guette, B. Barre, and O. Coqueret, STAT3 as a new autophagy regulator, JAK/STAT, vol.2, p.24353, 2013.